News | Ablation Systems | November 14, 2016

Catheter Ablations Reduce Long-Term Stroke Risk in Patients with Prior Stroke History

Intermountain study finds stroke rates similar between atrial fibrillation patients treated with ablation and patients with no history of AFib

catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association

November 14, 2016 — Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of a recurrent stroke by 50 percent, according to new research from the Intermountain Medical Center Heart Institute.

Atrial fibrillation is an abnormal heart rhythm caused by rogue electrical currents in the heart. The arrhythmia allows blood to pool and clot in the heart. When the clot breaks loose, it travels to the brain and causes a stroke.

When medications are not successful in treating the arrhythmia, catheter ablations are used to create scar tissue in the upper left atrium of the heart that prevents rapid, chaotic electric currents, often from the pulmonary veins, from causing the abnormal rhythm.

“One of the most devastating complications of atrial fibrillation is a stroke and its prevention is the treatment cornerstone of the abnormal heart rhythm,” said Jared Bunch, M.D., lead author of the study and director of electrophysiology at the Intermountain Medical Center Heart Institute in Salt Lake City. “Patients that have a prior history of stroke have a much greater risk of recurrent strokes. Our new research shows the more successful we are in treating the abnormal rhythm through the process required with catheter ablation, the better chance we have of lowering a patient’s long-term risk of stroke.”

Results of the study were presented during the American Heart Association’s Scientific Sessions, Nov. 12-16 in New Orleans.

The Intermountain study compared a group of 140 patients, who had a prior history of stroke and underwent their first catheter ablation, to two other patient groups, both of which also had a prior history of stroke, including 416 atrial fibrillation patients who did not receive a catheter ablation, and 416 stroke patients who did not have atrial fibrillation.

The patients were followed for five years and observed for recurrent outcomes of stroke, heart failure and death.

The five-year risk of patients having another stroke was decreased in the patients who had a catheter ablation to treat atrial fibrillation, compared to the group that had no catheter ablation to treat their abnormal heart rhythm. The stroke rates of atrial fibrillation patients that underwent an ablation procedure were similar to patients with no history of atrial fibrillation.

“One of the most important findings of this study was that stroke rates in patients that underwent an ablation were similar to patients with no history of atrial fibrillation. This suggests that our management approach can alter some of the negative effects and natural history of atrial fibrillation. As physicians, we spend a lot of our time and energy trying to prevent stroke. This study helps us understand better how our management approaches can alter stroke risk,” said Bunch. “Our research shows that more aggressive treatment of atrial fibrillation by using catheter ablations will reduce the chances a person will have a life-threatening stroke.”

Other members of the Intermountain Medical Center Heart Institute team include Heidi T. May, Ph.D.; Tami L. Bair, RN; Victoria Jacobs, Ph.D.; Brian G. Crandall, M.D.; Michael Cutler, M.D.; Jeffrey S. Osborn, M.D.; Charles Mallender, M.D.; John D. Day, M.D.; and Peter Weiss, M.D.

For more information: www.scientificsessions.org

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
Overlay Init